SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes PAI at Hyderabad facility of Granules India’s arm

02 Aug 2025 Evaluate

The U.S. Food & Drug Administration (USFDA) has concluded Pre-Approval Inspection (PAI) at Granules India’s wholly owned Indian subsidiary -- M/s Granules Life Sciences’ Hyderabad facility. The USFDA has conducted inspection from July 28, 2025 to August 01, 2025. The said facility has received one 483 observation, which is procedural in nature.

The Company will respond to this observation within the stipulated time. Granules Life Sciences is engaged in the manufacturing of PFI & Finished Dosages.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages.


Granules India Share Price

654.40 3.60 (0.55%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×